Nick Seewald, PhD
Nick Seewald, PhD
About
Research
Publications
Talks
People
Teaching
Software
Contact
Light
Dark
Automatic
Daniel F. Hayes
Latest with Nick
Prospective Assessment of Patient-Reported Outcomes and Estradiol and Drug Concentrations in Patients Experiencing Toxicity from Adjuvant Aromatase Inhibitors
Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women with Early Stage Breast Cancer
[Abstract] CYP3A4*22 polymorphism is associated with increased exemestane concentrations in postmenopausal breast cancer patients
[Abstract] Crossover from One Aromatase Inhibitor (AI) to Another in the Exemestane and Letrozole Pharmacogenetics (ELPh) Trial
Polymorphisms in Drug-Metabolizing Enzymes and Steady-State Exemestane Concentration in Postmenopausal Patients with Breast Cancer
[Abstract] Associations between treatment-emergent symptoms and early discontinuation of aromatase inhibitor (AI) therapy
Cite
×